Gene2Cure Collaborates with Viralgen to Manufacture Gene Therapies for Rare Diseases
- Gene2Cure Foundation has partnered with Viralgen to manufacture investigational gene therapies for rare genetic diseases.
- Viralgen will utilize its Aava platform for AAV manufacturing services, supporting both toxicology studies and clinical use.
Operational Impact
This collaboration enhances Viralgen's role in gene therapy manufacturing, potentially increasing capacity for rare disease treatments.
Source: PharmaSource RSS
OXB Partners with Aura Biosciences for Phase 3 Manufacturing of Ocular Cancer Therapy
- OXB has confirmed a manufacturing partnership with Aura Biosciences for belzupacap sarotalocan, an investigational therapy for ocular cancers.
- The collaboration will utilize OXB’s facilities in Bedford, Massachusetts, and Durham, North Carolina, for process performance qualification and commercial production.
Operational Impact
This partnership allows OXB to expand its manufacturing capabilities into virus-like drug conjugates while supporting Aura's late-stage clinical development.
Source: PharmaSource RSS